Active Surveillance for Men with Intermediate Risk Prostate Cancer COMMENT

被引：0
|
作者：
Chu, Carissa [1 ]
Carroll, Peter [1 ]
机构：
[1] Univ Calif San Francisco, UCSF Helen Diller Comprehens Canc Ctr, Dept Urol, San Francisco, CA 94143 USA
来源：
JOURNAL OF UROLOGY | 2021年 / 205卷 / 01期
关键词：
D O I：
10.1097/JU.0000000000001241.01
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：121 / 121
页数：1
相关论文
共 50 条
  • [41] Identifying intermediate-risk candidates for active surveillance of prostate cancer
    Savdie, Richard
    Aning, Jonathan
    So, Alan I.
    Black, Peter C.
    Gleave, Martin E.
    Goldenberg, S. Larry
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2017, 35 (10) : 605.e1 - 605.e8
  • [42] PROSTATE CANCER Time for active surveillance of intermediate-risk disease?
    Ahmed, Hashim U.
    NATURE REVIEWS UROLOGY, 2013, 10 (01) : 6 - 8
  • [43] Active surveillance for intermediate risk prostate cancer could be risky for the patient
    Moretti, Kim
    WORLD JOURNAL OF UROLOGY, 2022, 40 (04) : 1079 - 1080
  • [44] Is active surveillance safe for patients with intermediate-risk prostate cancer?
    Chung, Hoseok
    Shin, Bo Sung
    Nam, Deok-Hyun
    Chung, Hoseok
    Kim, Myung Ki
    Jung, Seung Il
    Kang, Taek Won
    Kwon, Dong Deuk
    BJU INTERNATIONAL, 2015, 116 : 4 - 4
  • [45] Active surveillance for intermediate-risk prostate cancer: yes, but for whom?
    Overland, Maya R.
    Washington, Samuel L., III
    Carroll, Peter R.
    Cooperberg, Matthew R.
    Herlemann, Annika
    CURRENT OPINION IN UROLOGY, 2019, 29 (06) : 605 - 611
  • [46] No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
    Karolina Cyll
    Sven Löffeler
    Birgitte Carlsen
    Karin Skogstad
    May Lisbeth Plathan
    Martin Landquist
    Erik Skaaheim Haug
    Scientific Reports, 12
  • [47] Intermediate-Term Outcomes for Men with Very Low/Low and Intermediate/High Risk Prostate Cancer Managed by Active Surveillance
    Nyame, Yaw A.
    Almassi, Nima
    Haywood, Samuel C.
    Greene, Daniel J.
    Ganesan, Vishnu
    Dai, Charles
    Zabell, Joseph
    Reichard, Chad
    Arora, Hans
    Zampini, Anna
    Crane, Alice
    Hettel, Daniel
    Elshafei, Ahmed
    Fareed, Khaled
    Stein, Robert J.
    Berglund, Ryan K.
    Gong, Michael
    Jones, J. Stephen
    Klein, Eric A.
    Stephenson, Andrew J.
    JOURNAL OF UROLOGY, 2017, 198 (03): : 591 - 598
  • [48] No significant difference in intermediate key outcomes in men with low- and intermediate-risk prostate cancer managed by active surveillance
    Cyll, Karolina
    Loffeler, Sven
    Carlsen, Birgitte
    Skogstad, Karin
    Plathan, May Lisbeth
    Landquist, Martin
    Haug, Erik Skaaheim
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [49] PREDICTED RISK OF PROSTATE CANCER-SPECIFIC MORTALITY ON ACTIVE SURVEILLANCE FOR MEN WITH FAVORABLE INTERMEDIATE RISK PROSTATE CANCER: RESULTS FROM THE SEARCH DATABASE
    Kuhlmann, Paige K.
    Oyekunle, Taofik
    Howard, Lauren E.
    Klaassen, Zachary
    Amling, Christopher L.
    Aronson, William J.
    Cooperberg, Matthew R.
    Kane, Christopher J.
    Terris, Martha K.
    Freedland, Stephen J.
    JOURNAL OF UROLOGY, 2020, 203 : E1289 - E1289
  • [50] Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men
    Courtney, P. Travis
    Deka, Rishi
    Kotha, Nikhil, V
    Cherry, Daniel R.
    Salans, Mia A.
    Nelson, Tyler J.
    Kumar, Abhishek
    Luterstein, Elaine
    Yip, Anthony T.
    Nalawade, Vinit
    Parsons, J. Kellogg
    Kader, A. Karim
    Stewart, Tyler F.
    Rose, Brent S.
    CANCER, 2021, 127 (23) : 4403 - 4412
12345